<DOC>
	<DOCNO>NCT01838460</DOCNO>
	<brief_summary>To compare subject 's AUCinf , administration one single dose 6 mg Nicorette sublingual nicotine tablet ( three 2mg tablet ) one single 1 g dose SS contain 16 mg nicotine .</brief_summary>
	<brief_title>Sublingual Nicotine Tablets Compared With Swedish Snus</brief_title>
	<detailed_description>Open , randomize , five-way cross-over . Single dose administration . The Nicorette 6 mg sublingual tablet three strength SS test . Subjects 18-50 year old , male/female ( non-pregnant ) , healthy volunteer , use minimum 12 pouch 1 g portion snus half loose snus per day . The treatment give single dos randomize order . The subject keep sublingual tablet still tongue 30 minute . The subject keep pouch ( e ) snus still upper lip gum 30 minute . Serial blood sample draw , regular time interval 6 hour administration . Amount nicotine extract , plasma nicotine concentration 30 minute ( C30 ) , Tmax , Cmax , AUCinf heart rate treatment . The AUCinf area base plasma data correct background nicotine ( time zero sample ) . Each subject 's rating subjective effect use Visual Analogue Scale ( VAS ) palm top computer , anchor `` '' `` extremely '' . VAS score obtain plasma concentration sample time point 30 minute : - crave intensity - overall `` product strength '' ( head rush , `` buzz '' , `` hit '' , feel alert ) - increase salivation - burning sensation mouth and/or throat</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Lobeline</mesh_term>
	<criteria>1 . Consent participate voluntarily sign Informed Consent Form prior study procedure . 2 . Healthy male/female , age 18 50 year . Female use contraceptive pill negative pregnancy test . 3 . Willing able comply study procedure . 4 . Snus user , minimum 12 pouch half loose snus per day pouch portion snus , minimum 1 gram/portion . 5 . Abstinent form nicotine use 8.00 p.m. 6 . Fasting overnight 11.00 p.m. 1 . Smoker , define `` smoking last 24 hour accord self report CO exhale air &gt; 10 ppm clinical visit '' 2 . Second third degree AV block sick sinus syndrome ; congestive heart failure classify functional Class III IV New York Heart Association ; myocardial infarction within six month baseline ; prolong QTc interval screen pretreatment ( define QTc interval &gt; 450 msec male &gt; 470 msec female ) ; clinically significant heart condition would negatively impact subject complete study . 3 . Subjects clinically significant liver disease may prevent subject complete study and/or elevation total bilirubin , alkaline phosphatase , LDH , ASAT , ALAT &gt; 3 time upper limit laboratory reference interval . 4 . Subjects clinically significant renal disease may prevent subject complete study and/or elevation serum creatinine &gt; 1.5 time laboratory reference . 5 . Surgery within 6 month Baseline visit , opinion investigator , could negatively impact subject 's participation clinical study . 6 . Subjects participate drug study within 30 day prior enrolment . 7 . Subjects surgical medical condition , , judgment clinical investigator , might interfere absorption , distribution , metabolism excretion drug . 8 . Subjects use drug capable induce hepatic enzyme metabolism within previous 30 day ( 5 half life induce agent , whichever long ) enrolment study . 9 . Subjects medical history seizure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>